Dongguan HEC Pharm RD

Dongguan HEC Pharm R&D is a leading Chinese pharmaceutical research and development company and a key subsidiary of Sunshine Lake Pharma (HEC Group). Established in 2002, the company focuses on the discovery, preclinical, and clinical development of innovative small molecules and biologics across therapeutic areas such as endocrinology, metabolic diseases, oncology, and infectious diseases. Its pipeline features advanced candidates including clifutinib (HEC73543), a highly selective second-generation FLT3 inhibitor in Phase 3 for relapsed/refractory acute myeloid leukemia, and HEC88473 (APL-18881), a dual GLP-1/FGF21 receptor agonist in Phase 2 for type 2 diabetes and metabolic liver diseases. In January 2026, its SGLT2/SGLT1 inhibitor ologliptin (Dongze'an) received NMPA approval in China for type 2 diabetes, marking a major commercial milestone. The company leverages its extensive R&D infrastructure and strategic partnerships, such as collaborations with Apollo Therapeutics and 3SBio, to advance and commercialize its innovative therapeutic portfolio globally.